secwatch.observer — SEC 8-K summary
======================================

Issuer:     Semnur Pharmaceuticals, Inc. (SMNR)
CIK:        0001913577
Form:       8-K
Filed at:   2025-04-09T23:59:59+00:00
Accession:  0001213900-25-030048
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali Capital receives Nasdaq delisting determination; must appeal by April 9 or face suspension
--------------------------------------------------------------------------------

- On April 2, 2025, Nasdaq staff determined Denali failed to meet MVLS, total assets, and public float rules.
- Company must appeal by April 9, 2025 to avoid delisting; if no appeal, trading suspended April 11, 2025.
- Company expects to trade on OTC market after delisting; plans to remain a reporting company.
- Delisting not expected to immediately impact planned business combination with Semnur Pharmaceuticals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1913577/000121390025030048/0001213900-25-030048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1913577/000121390025030048/ea0237665-8k425_denali.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-030048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer